الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 198 |  |  |
| | | from | 198 | | |
Abstract
Diabetes mellitus and hypertension are both common disorders and it could be anticipated that they coexist in many patients. The clinical importance of selection of different antihypertensive drugs for the diabetic patient is still under consideration the use of beta blockers in diabetes mellitus has largely been restricted because of adverse effects. In this study we try to study the effect of the non-selective B-blocker propranolol and cardioselective drug atenelol alone or with concurrent treatment with oral hypoglycaemic drug (Glibenclamide on some biochemical parameters as glucose, lactate, insulin, glucagon, free fatty acid, high denesitylipoprotein, low density lipoprotein, cholesterols, and triacyleglycerol at streptozotocin diabetic rat. A total of 80 adult male albino white rats are used in this studies. This rats are divided into 8 groups (each- of 10 rats).
I-First group: Control group without treatment.
II-Second group:
Rats of this group are treated with propranolol (Inderal) at dose 5 mg/kg B.V. orally/daily.
III-Third group:
Rats of this group are treated with atenelol (tenormin) at a dose of 9 mg/kg B.W. / orally/daily.
IV-Diabetic groups:
Are 50 rats are injected with STZ at dose 60 mg/kg B.W for one time only I/P. This groups are divided into 5 subgroup (each of 10 rats).
a-Subgroup (1):
This group of rats are treated with propranolol at dose of 5 mg/kg B.W./orally daily.
b-Subgroup (2):
This group of rats are treated with atenelol at dose 9 mg/kg B.W. /orally/daily.
c-Subgroup (3):
This group of rats are treated with gliben clamide at a dose of 2.5 mg/kg B.W. /orally/daily.
d-Subgroup (4):
This group of rats are treated with glibenclamide at dose 2.5 mg/kg B.W. /orally /daily and propranolol at a dose of 5 mg/kg B.W./ orally/daily.
e-Subgroup (5):
This group of rats are treated with glibenclamide at dose of 2.5 mg/kg B.W./orally/daily and atenelol at dose of 9 mg/kg B.W./ orally/daily. All rats are treated for 60 days. Blood samples are collected for biochemical analysis of:
1-Serum glucose
2-Serum lactate
3-Serum insulin
4-Serum glucagon.
5-Serum free fatty acid
6-Serum low density lipoprotein
7-Serum high denesity lipoprotein.
8-Serum cholesterol
9-Serum triacyleglycerol.
Then the obtained results are:
1-Very highly significant increase of serum glucose level in rats after injection single dose of STZ in comparison to control at 48 hrs.
- Very highly significant increase of serum glucose level indiabetic rats treated by propranolol at 15, 30 and 60 days post STZ injection in comparison to normal rats administrated propranolol.
- There was high significant decrease of glucose level P> 0.01 in diabetic rats after administration of atenelol, propranlol alone and with a combination with glibenclaminde and glibenclamide alone. In normal rats: atenelol and propranolol had no effect on glucose level.
2-There was high significant increase of blood lactate with glibenclamide P >0.01.
3-There was insignificant change in serum insulin with administration of atenelol, propranolol and glibenclamide.
4-There was highly significant increase P > 0.01 serum glucagon with treatment of glibenclamide with atenelol and propranolol in diabetic rats at 60 days.
- Significant decrease of serum glucagon by combination of glibenclamide with propranolol at 15 days.
- High significant increase of serum glucagon after treatment with propanolol at 60 days.
5-High significant decrease of FFA P > 0.01, with administration of atenelol, propronolol alone and with combination with glibenchmide to diabetic rats P > 0.01.
- High significant decrease of FFA P > 0.01 with atenelol and propranolol in normal rats:
6-There was significant decrease P > 0.05 of cholesterol level with administration of propranolol, atenelol, glibenclamide alone and with combination of atenelol with glibenclamide.
- Highly significant decrease P > 0.01 of cholesterol with time from 15 to 30 to 60 days.
7-There was highly significant decrease of triacyleglycerol P > 0.01 by administration of propranolol, atenelol, glibenclamide and their concurrent treatment from 15 to 30 to 60 days.
8-High significant decrease of HDL P > 0.01 with administration of atenelol to diabetic rats.
- Significant decrease of HDL by administration of atenelol to normal rats.
9-High significant decrease of LDL from 15 to 30 to 60 days.